UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science [TheStreet.com]
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: TheStreet.com
PR Newswire ATLANTA, April 17, 2026 Acquisition builds on UCB's 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies. Lead investigational asset, NRTX-1001, a neuronal cell therapy, is being evaluated in phase I/II clinical trials for drug-resistant mesial temporal lobe epilepsy Temporal lobe epilepsy – the most common type of focal epilepsy - remains a high burden condition with significant unmet need, affecting memory, emotion, behavior, and daily functioning. Total transaction value of up to US $1.15b consisting of a US $650m upfront payment plus up to US $500m in potential future milestone payments. 2026 revenue guidance remains unchanged. 2026 underlying profitability, as measured by adjusted EBITDA, is now expected to grow in a high single-digit to mid-teens percentage range at constant exchange rates (CER). ATLANTA April 17, 2026 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global bi
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative sciencePR Newswire
- UCB (UCBJY) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting [TheStreet.com]TheStreet.com
- UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meetingPR Newswire
- UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meetingPR Newswire